

EO-011

A DELIVERY SYSTEM OF SMPSH FOR ORAL ADMINISTRATION OF ANTI-CANCER AGENT, PACLITAXEL

Jong-Suep Baek¹ and Sang-Chul Shin², Cheong-Weon Cho¹

- 1) College of Pharmacy, Chungnam National University, Daejeon 305-764, Korea
- 2) College of Pharmacy, Chonnam National University, Gwangju 500-757, Korea

ABSTRACT

Clinical application of paclitaxel (PTX) in the treatment of cancer is limited because of its poor bioavailability. The objectives of this study were to evaluate the potential of surface-modified PTX-incorporated solid lipid nanoparticles with hydroxypropyl beta cyclodextrin (smPSH). The smPSH showed an 89.70 ± 3.99% of release of PTX in dissolution medium including sodium lauryl sulfate (SLS) in 24 h and 5.3-fold increase in the cellular uptake of PTX compared to PTX solution in Caco-2 cells. Moreover, smPSH exhibited more cytotoxicity than PTX solution. Also, AUC (5.43 µg·h/mL) and C_{max} (1.44 µg/mL) of smPSH were higher than those (1.81 µg·h/mL and 0.73 µg/mL) of PTX solution according to Taxol formulation and drug concentration of smPSH (11.12- 4.45 ng/mg of lymph tissue) in lymph nodes was higher than PTX solution (0.89-0.75 ng/mg of lymph tissue), suggesting more PTX was transported to lymphatic vessel delivery in the form of smPSH. Taken together, smPSH have a potential as alternative delivery system for oral administration of PTX.

Acknowledgments

This work was supported by the Priority Research Centers Program (2009-0093815) and the Basic Science Research Program (2009-0067380) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.

Reproduced with permission of copyright
owner. Further reproduction prohibited
without permission.